Fear of Cancer Recurrence in Sarcoma Survivors: Results from the SURVSARC Study

Ilaria Pellegrini; Cas Drabbe; Dirk J Grünhagen; Michiel A J Van de Sande; Jacco J de Haan; Kristien B M I Keymeulen; Johannes J Bonenkamp; Winette T A Van der Graaf; Olga Husson

doi:10.3390/cancers14246099

Fear of Cancer Recurrence in Sarcoma Survivors: Results from the SURVSARC Study

Ilaria Pellegrini, Cas Drabbe, Dirk J Grünhagen, Michiel A J Van de Sande, Jacco J de Haan, Kristien B M I Keymeulen, Johannes J Bonenkamp, Winette T A Van der Graaf, Olga Husson^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

UNLABELLED: Fear of cancer recurrence (FCR) is often reported as an unmet concern by cancer patients. The aim of our study was to investigate (1) the prevalence of FCR in sarcoma survivors; (2) the factors associated with a higher level of FCR; the relationship between (3) FCR and global health status and (4) FCR and use of follow-up care.

METHODS: A cross-sectional study was conducted among sarcoma survivors 2 to 10 years after diagnosis. Patients completed the Cancer Worry Scale (CWS), the global health status subscale of the EORTC QLQ-C30 and a custom-made questionnaire on follow-up care.

RESULTS: In total, 1047 patients were included (response rate 55%). The prevalence of high FCR was 45%. Factors associated with high FCR were female sex with 1.6 higher odds (95% CI 1.22-2.25; p = 0.001); having ≥1 comorbidities and receiving any treatment other than surgery alone with 1.5 (95% CI 1.07-2.05; p = 0.017) and 1.4 (95% CI 1.06-1.98; p = 0.020) higher odds, respectively. Patients on active follow-up had 1.7 higher odds (95% CI 1.20-2.61; p = 0.004) and patients with higher levels of FCR scored lower on the global health status scale (72 vs. 83 p ≤ 0.001).

CONCLUSIONS: Severe FCR is common in sarcoma survivors and high levels are related to a decreased global health status. FCR deserves more attention in sarcoma survivorship, and structured support programs should be developed to deliver interventions in a correct and time adequate environment.

Original language	English
Article number	6099
Number of pages	14
Journal	Cancers
Volume	14
Issue number	24
DOIs	https://doi.org/10.3390/cancers14246099
Publication status	Published - 11 Dec 2022

Access to Document

10.3390/cancers14246099Licence: CC BY

Cite this

@article{888e9a3911654397bd876dafbbdb7867,

title = "Fear of Cancer Recurrence in Sarcoma Survivors: Results from the SURVSARC Study",

abstract = "UNLABELLED: Fear of cancer recurrence (FCR) is often reported as an unmet concern by cancer patients. The aim of our study was to investigate (1) the prevalence of FCR in sarcoma survivors; (2) the factors associated with a higher level of FCR; the relationship between (3) FCR and global health status and (4) FCR and use of follow-up care.METHODS: A cross-sectional study was conducted among sarcoma survivors 2 to 10 years after diagnosis. Patients completed the Cancer Worry Scale (CWS), the global health status subscale of the EORTC QLQ-C30 and a custom-made questionnaire on follow-up care.RESULTS: In total, 1047 patients were included (response rate 55%). The prevalence of high FCR was 45%. Factors associated with high FCR were female sex with 1.6 higher odds (95% CI 1.22-2.25; p = 0.001); having ≥1 comorbidities and receiving any treatment other than surgery alone with 1.5 (95% CI 1.07-2.05; p = 0.017) and 1.4 (95% CI 1.06-1.98; p = 0.020) higher odds, respectively. Patients on active follow-up had 1.7 higher odds (95% CI 1.20-2.61; p = 0.004) and patients with higher levels of FCR scored lower on the global health status scale (72 vs. 83 p ≤ 0.001).CONCLUSIONS: Severe FCR is common in sarcoma survivors and high levels are related to a decreased global health status. FCR deserves more attention in sarcoma survivorship, and structured support programs should be developed to deliver interventions in a correct and time adequate environment.",

author = "Ilaria Pellegrini and Cas Drabbe and Gr{\"u}nhagen, {Dirk J} and {Van de Sande}, {Michiel A J} and {de Haan}, {Jacco J} and Keymeulen, {Kristien B M I} and Bonenkamp, {Johannes J} and {Van der Graaf}, {Winette T A} and Olga Husson",

note = "Funding Information: The PROFILES registry was funded by an Investment Grant Medium (#480-08-009) of the Netherlands Organization for Scientific Research (The Hague, the Netherlands). The present research was supported by an Investment Grant Large 2016/04981/ZONMW-91101002) of the Netherlands Organization for Scientific Research (The Hague, the Netherlands). Olga Husson is supported by a Social Psychology Fellowship from the Dutch Cancer Society (#KUN2015-7527) and Netherlands Organization for Scientific Research VIDI grant (198.007). Publisher Copyright: {\textcopyright} 2022 by the authors.",

year = "2022",

month = dec,

day = "11",

doi = "10.3390/cancers14246099",

language = "English",

volume = "14",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "24",

}

TY - JOUR

T1 - Fear of Cancer Recurrence in Sarcoma Survivors

T2 - Results from the SURVSARC Study

AU - Pellegrini, Ilaria

AU - Drabbe, Cas

AU - Grünhagen, Dirk J

AU - Van de Sande, Michiel A J

AU - de Haan, Jacco J

AU - Keymeulen, Kristien B M I

AU - Bonenkamp, Johannes J

AU - Van der Graaf, Winette T A

AU - Husson, Olga

N1 - Funding Information: The PROFILES registry was funded by an Investment Grant Medium (#480-08-009) of the Netherlands Organization for Scientific Research (The Hague, the Netherlands). The present research was supported by an Investment Grant Large 2016/04981/ZONMW-91101002) of the Netherlands Organization for Scientific Research (The Hague, the Netherlands). Olga Husson is supported by a Social Psychology Fellowship from the Dutch Cancer Society (#KUN2015-7527) and Netherlands Organization for Scientific Research VIDI grant (198.007). Publisher Copyright: © 2022 by the authors.

PY - 2022/12/11

Y1 - 2022/12/11

N2 - UNLABELLED: Fear of cancer recurrence (FCR) is often reported as an unmet concern by cancer patients. The aim of our study was to investigate (1) the prevalence of FCR in sarcoma survivors; (2) the factors associated with a higher level of FCR; the relationship between (3) FCR and global health status and (4) FCR and use of follow-up care.METHODS: A cross-sectional study was conducted among sarcoma survivors 2 to 10 years after diagnosis. Patients completed the Cancer Worry Scale (CWS), the global health status subscale of the EORTC QLQ-C30 and a custom-made questionnaire on follow-up care.RESULTS: In total, 1047 patients were included (response rate 55%). The prevalence of high FCR was 45%. Factors associated with high FCR were female sex with 1.6 higher odds (95% CI 1.22-2.25; p = 0.001); having ≥1 comorbidities and receiving any treatment other than surgery alone with 1.5 (95% CI 1.07-2.05; p = 0.017) and 1.4 (95% CI 1.06-1.98; p = 0.020) higher odds, respectively. Patients on active follow-up had 1.7 higher odds (95% CI 1.20-2.61; p = 0.004) and patients with higher levels of FCR scored lower on the global health status scale (72 vs. 83 p ≤ 0.001).CONCLUSIONS: Severe FCR is common in sarcoma survivors and high levels are related to a decreased global health status. FCR deserves more attention in sarcoma survivorship, and structured support programs should be developed to deliver interventions in a correct and time adequate environment.

AB - UNLABELLED: Fear of cancer recurrence (FCR) is often reported as an unmet concern by cancer patients. The aim of our study was to investigate (1) the prevalence of FCR in sarcoma survivors; (2) the factors associated with a higher level of FCR; the relationship between (3) FCR and global health status and (4) FCR and use of follow-up care.METHODS: A cross-sectional study was conducted among sarcoma survivors 2 to 10 years after diagnosis. Patients completed the Cancer Worry Scale (CWS), the global health status subscale of the EORTC QLQ-C30 and a custom-made questionnaire on follow-up care.RESULTS: In total, 1047 patients were included (response rate 55%). The prevalence of high FCR was 45%. Factors associated with high FCR were female sex with 1.6 higher odds (95% CI 1.22-2.25; p = 0.001); having ≥1 comorbidities and receiving any treatment other than surgery alone with 1.5 (95% CI 1.07-2.05; p = 0.017) and 1.4 (95% CI 1.06-1.98; p = 0.020) higher odds, respectively. Patients on active follow-up had 1.7 higher odds (95% CI 1.20-2.61; p = 0.004) and patients with higher levels of FCR scored lower on the global health status scale (72 vs. 83 p ≤ 0.001).CONCLUSIONS: Severe FCR is common in sarcoma survivors and high levels are related to a decreased global health status. FCR deserves more attention in sarcoma survivorship, and structured support programs should be developed to deliver interventions in a correct and time adequate environment.

U2 - 10.3390/cancers14246099

DO - 10.3390/cancers14246099

M3 - Article

C2 - 36551585

SN - 2072-6694

VL - 14

JO - Cancers

JF - Cancers

IS - 24

M1 - 6099

ER -